CXCR4 and CD74 together enhance cell survival in response to macrophage migration-inhibitory factor in chronic lymphocytic leukemia.

Humans Mice Animals Leukemia, Lymphocytic, Chronic, B-Cell / pathology Cell Survival Antigens, Differentiation, B-Lymphocyte / metabolism Histocompatibility Antigens Class II / metabolism Receptors, CXCR4 / genetics Macrophages / metabolism Tumor Microenvironment

Journal

Experimental hematology
ISSN: 1873-2399
Titre abrégé: Exp Hematol
Pays: Netherlands
ID NLM: 0402313

Informations de publication

Date de publication:
11 2022
Historique:
received: 30 07 2021
revised: 16 08 2022
accepted: 29 08 2022
pubmed: 13 9 2022
medline: 8 11 2022
entrez: 12 9 2022
Statut: ppublish

Résumé

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of small, mature CD5

Identifiants

DOI: 10.1016/j.exphem.2022.08.005 PMID: 36096455
pubmed: 36096455
pii: S0301-472X(22)00681-6
doi: 10.1016/j.exphem.2022.08.005
pii:
doi:

Substances chimiques

invariant chain 0
Antigens, Differentiation, B-Lymphocyte 0
Histocompatibility Antigens Class II 0
Receptors, CXCR4 0
CXCR4 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

30-43

Informations de copyright

Copyright © 2022 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest disclosure This work was partly supported by the Deutsche Forschungsgemeinschaft (DFG) within the framework of Munich Cluster for Systems Neurology (EXC 1010 SyNergy) to JB. We also acknowledge partial support from DFG Grants SFB1123/A03 and LMUexcellent (strategic partnership Munich–Singapore) to JB.

Auteurs

Tharshika Thavayogarajah (T)

Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Rheinisch-Westfälische Technische (RWTH) Aachen University, Aachen, Germany; Department of Vascular Biology, Institute for Stroke and Dementia Research (ISD), Klinikum der Universität München, Ludwig-Maximilians University Munich, Munich, Germany; Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland.

Dzmitry Sinitski (D)

Department of Vascular Biology, Institute for Stroke and Dementia Research (ISD), Klinikum der Universität München, Ludwig-Maximilians University Munich, Munich, Germany.

Omar El Bounkari (O)

Department of Vascular Biology, Institute for Stroke and Dementia Research (ISD), Klinikum der Universität München, Ludwig-Maximilians University Munich, Munich, Germany.

Laura Torres-Garcia (L)

Department of Vascular Biology, Institute for Stroke and Dementia Research (ISD), Klinikum der Universität München, Ludwig-Maximilians University Munich, Munich, Germany.

Hadas Lewinsky (H)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Alexander Harjung (A)

Department of Vascular Biology, Institute for Stroke and Dementia Research (ISD), Klinikum der Universität München, Ludwig-Maximilians University Munich, Munich, Germany.

Hong-Ru Chen (HR)

Department of Vascular Biology, Institute for Stroke and Dementia Research (ISD), Klinikum der Universität München, Ludwig-Maximilians University Munich, Munich, Germany.

Jens Panse (J)

Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Rheinisch-Westfälische Technische (RWTH) Aachen University, Aachen, Germany.

Lucia Vankann (L)

Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Rheinisch-Westfälische Technische (RWTH) Aachen University, Aachen, Germany.

Idit Shachar (I)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Jürgen Bernhagen (J)

Department of Vascular Biology, Institute for Stroke and Dementia Research (ISD), Klinikum der Universität München, Ludwig-Maximilians University Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany; SyNergy Excellence Cluster, Munich, Germany. Electronic address: juergen.bernhagen@med.uni-muenchen.de.

Steffen Koschmieder (S)

Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Rheinisch-Westfälische Technische (RWTH) Aachen University, Aachen, Germany. Electronic address: skoschmieder@ukaachen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › CXCR4 and CD74 together enhance cell survival...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › CXCR4 and CD74 together enhance cell survival...
questionsmedicales.fr › Eucaryotes › Animaux › CXCR4 and CD74 together enhance cell survival...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Leucémie chronique lymphocytaire à cellules B › CXCR4 and CD74 together enhance cell survival...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › CXCR4 and CD74 together enhance cell survival...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes B › CXCR4 and CD74 together enhance cell survival...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes d'histocompatibilité de classe II › CXCR4 and CD74 together enhance cell survival...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs viraux › Récepteur VIH › Récepteurs CXCR4 › CXCR4 and CD74 together enhance cell survival...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Macrophages › CXCR4 and CD74 together enhance cell survival...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › CXCR4 and CD74 together enhance cell survival...